Physician profile
Hailey Barron
NPI 1235834920
$7,002.11
in general payments reported to CMS, 2019-2025
40 companies · $3,010 in 2025
The $3,010 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,041 · 2024: $2,951 · 2025: $3,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,803 · Education: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,803.17 |
| Education | $1,198.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,063.79 | 2023-2025 | Darzalex, Tecvayli, Imbruvica |
| Abbvie INC. | $632.66 | 2023-2025 | |
| Incyte Corporation | $494.00 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $424.20 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $410.00 | 2023-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $408.73 | 2023-2024 | Reblozyl, Opdivo, Opdualag |
| Genzyme Corporation | $384.66 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $383.93 | 2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $374.59 | 2024-2025 | |
| Lilly USA, LLC | $188.90 | 2024-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $169.29 | 2024-2025 | Trodelvy |
| Sobi, INC | $163.63 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $142.75 | 2024-2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $136.05 | 2024-2025 | Libtayo |
| Geron Corporation | $125.93 | 2025 | Rytelo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $125.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $121.98 | 2024-2025 | Enhertu, Lynparza |
| Pfizer INC. | $117.70 | 2024-2025 | |
| Legend Biotech USA INC. | $109.74 | 2024-2025 | Carvykti |
| Genentech USA, INC. | $109.73 | 2023-2025 | Tecentriq, Itovebi, Lunsumio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Seagen INC. | $99.00 | 2025 | |
| Astellas Pharma US INC | $93.95 | 2025 | |
| Stemline Therapeutics INC. | $75.39 | 2024-2025 | Orserdu |
| Exelixis INC. | $74.67 | 2024-2025 | Cabometyx |
| Taiho Oncology, INC. | $64.78 | 2023-2025 | |
| Glaxosmithkline, LLC. | $64.37 | 2024-2025 | Ojjaara |
| Genmab U.S., INC. | $63.13 | 2025 | Tivdak |
| Jazz Pharmaceuticals INC. | $48.70 | 2024 | |
| Eisai INC. | $43.04 | 2024 | |
| Beone Medicines USA, INC. | $22.40 | 2025 | Tevimbra |
| Servier Pharmaceuticals LLC | $22.38 | 2025 | |
| Beigene USA, INC. | $22.15 | 2024 | Tevimbra |
| Kyowa Kirin, INC. | $18.41 | 2024 | Poteligeo |
| Tolmar, INC. | $17.72 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $17.72 | 2025 | Rubraca |
| Syndax Pharmaceuticals, INC. | $17.26 | 2025 | |
| Puma Biotechnology, INC. | $17.14 | 2024 | |
| Tersera Therapeutics LLC | $16.70 | 2025 | Zoladex |
| Celgene Corporation | $15.84 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.